Tirzepatide
China [CN] tirzepatide is a novel dual-receptor agonist of glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulin-stimulating polypeptide (GIP, also known as: gastric inhibitory polypeptide), administered once a week. Both GLP-1 and GIP belong to enteropancreatic hormones, which are polypeptides secreted by the mucous membranes of the human gastrointestinal tract. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby exerting a hypoglycemic effect. It can also delay gastric emptying and suppress appetite, thereby controlling weight. The latter has functions such as inhibiting the secretion of gastric acid and pepsin, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the effect of GLP-1 receptor agonists. tirzepatide integrates the effects of two insulin-stimulating drugs into a single molecule, representing a new type of drug for the treatment of type 2 diabetes.
Click enlarge Image